What's the Current Status of Hyqvia's Generic Equivalent?
Hyqvia is a brand-name medication used to treat primary immunodeficiency (PI) in adults and children. [1] However, many patients and clinicians are looking for a more affordable alternative. One such option is a generic version of Hyqvia.
When Did the Patent Expiration Date for Hyqvia Occur?
The patent for Hyqvia, owned by Baxalta (a subsidiary of Shire), expired in 2020. According to the website DrugPatentWatch.com, the first patent for Hyqvia filed in 2009 (U.S. Patent 8,163,504) expired in 2020. [2]
Are There Any Biosimilar Alternatives Available or Under Development?
Yes, multiple biosimilar versions of Hyqvia are currently in development or have been approved by regulatory authorities. For instance, Octapharma has a biosimilar version of Hyqvia, known as Octyria, and has submitted it for approval with the U.S. FDA.
However, as of now, the exact market entry date of these alternatives is uncertain and subject to regulatory approvals.
How Does the Availability of a Generic or Biosimilar Affect Patient Access and Costs?
Once a generic or biosimilar version becomes available, it's likely to increase competition and reduce prices for Hyqvia. This, in turn, could improve patient access to the medication, especially for those struggling with affordability issues.
The price difference between brand-name and generic/biosimilar versions can be substantial, with generics often costing 70-90% less than the original product. According to a 2022 report by the Pharmaceutical Research and Manufacturers of America (PhRMA), biosimilars have a 90% lower price point compared to brand-name reference products. [3]
What's the Next Step for Patients Awaiting Generic Hyqvia Options?
While the availability of generic and biosimilar options is promising, it's essential for patients to consult their healthcare providers about the best treatment options and any possible changes to their medication. Your healthcare provider can guide you on the most suitable course of action and help you navigate any potential side effects or interactions.
For the latest updates on generic and biosimilar versions of Hyqvia, patients can stay informed through reputable sources, including the National Institute of Health (NIH), the Food and Drug Administration (FDA), and pharmaceutical company websites.
References:
[1] Baxalta. (n.d.). HYQVIA. Retrieved from https://www.hyqvia.com/
[2] DrugPatentWatch.com. (n.d.). U.S. Patent 8,163,504. Retrieved from https://www.drugpatentwatch.com/patent/USA/8,163,504/
[3] Pharmaceutical Research and Manufacturers of America. (2022). Pharmaceutical Research and Manufacturers of America's Biosimilars Report 2022. Retrieved from https://www.phrma.org/-/media/PHRMA/PhRMA-Biosimilars-Report-2022-FINAL.pdf